Brief summaries of recent medtech market and industry developments. This month we cover FDA panels' thumbs-down rulings on Styker's OP1-Putty and Therox's SuperSaturated Oxygen Therapy System, a potential curb on payments for negative pressure wound therapy pumps, CMS' review of carotid stenting coverage, and Abbott Vascular move into the second phase of its ABSORB trial for its drug-eluting stent.

Brief summaries of recent medtech market and industry developments. This month we cover FDA panels' thumbs-down rulings on Styker's OP1-Putty and Therox's SuperSaturated Oxygen Therapy System, a potential curb on payments for negative pressure wound therapy pumps, CMS' review of carotid stenting coverage, and Abbott Vascular move into the second phase of its ABSORB trial for its drug-eluting stent.

The aortic endograft market stands out in the medical device arena for its rich history of failure. The number of products that have been pulled from the market or axed before they reached it exceeds the number of models currently available in the US. But despite these past failures, endovascular aortic procedures have thrived thanks to researchers’ tenacity. At this year's International Congress on Endovascular Interventions, top surgeons discussed a number of new devices and techniques aimed at widening the scope of endovascular aortic repair to a broader range of patients.